There was some earlier conjecture on the size of the market and potential annual future sales for ReCell re: interview with Bill Dolphin. Re-listening to the interview, Dolphin discusses the different market segments which ReCell is targeting - chronic wounds, burns and cosmetic applications e.g. wrinkles, acne scarring.
"We can see that, on the order of 10-12 million procedures will be done per year utilising ReCell," said Dolphin.
The number of ReCell kits which Dolphin can visualize being sold is 10-12 million annually. Assuming a sales value per kit of $750, Dolphin is projecting a future turnover of $7.5B. Of course the future could be 5-15 years away. The sheer scale of the market and the revolutionary impact of the ReCell procedure will - at some point in time - make Avita Medical a hotly contested takeover target. Of course, as Dolphin appears to suggest in the interview - that's the whole point.
AVH Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)